• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

里尔模型:用于接受类固醇治疗的重症酒精性肝炎患者治疗策略的新工具。

The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.

作者信息

Louvet Alexandre, Naveau Sylvie, Abdelnour Marcelle, Ramond Marie-José, Diaz Emmanuel, Fartoux Laetitia, Dharancy Sébastien, Texier Frédéric, Hollebecque Antoine, Serfaty Lawrence, Boleslawski Emmanuel, Deltenre Pierre, Canva Valérie, Pruvot François-René, Mathurin Philippe

机构信息

Services d'Hépato-Gastroentérologie, Hôpital Claude Huriez, Avenue Michel Polonovski, CHRU Lille, 59037 Lille, France.

出版信息

Hepatology. 2007 Jun;45(6):1348-54. doi: 10.1002/hep.21607.

DOI:10.1002/hep.21607
PMID:17518367
Abstract

UNLABELLED

Early identification of patients with severe (discriminant function > or = 32) alcoholic hepatitis (AH) not responding to corticosteroids is crucial. We generated a specific prognostic model (Lille model) to identify candidates early on for alternative therapies. Three hundred twenty patients with AH prospectively treated by corticosteroids were included in the development cohort and 118 in its validation. Baseline data and a change in bilirubin at day 7 were tested. The model was generated by logistic regression. The model combining six reproducible variables (age, renal insufficiency, albumin, prothrombin time, bilirubin, and evolution of bilirubin at day 7) was highly predictive of death at 6 months (P < 0.000001). The area under the receiver operating characteristic (AUROC) curve of the Lille model was 0.89 +/- 0.02, higher than the Child-Pugh (0.62 +/- 0.04, P < 0.00001) or Maddrey scores (0.66 +/- 0.04, P < 0.00001). In the validation cohort, its AUROC was 0.85 +/- 0.04, still higher than the other models, including MELD (0.72 +/- 0.05, P = 0.01) and Glasgow scores (0.67 +/- 0.05, P = 0.0008). Patients above the ideal cutoff of 0.45 showed a marked decrease in 6-month survival as compared with others: 25% +/- 3.8% versus 85% +/- 2.5%, P < 0.0001. This cutoff was able to identify approximately 75% of the observed deaths.

CONCLUSION

In the largest cohort to date of patients with severe AH, we demonstrate that the term "nonresponder" can now be extended to patients with a Lille score above 0.45, which corresponds to 40% of cases. Early identification of subjects with substantial risk of death according to the Lille model will improve management of patients suffering from severe AH and will aid in the design of future studies for alternative therapies.

摘要

未标注

早期识别对皮质类固醇无反应的重度(判别函数≥32)酒精性肝炎(AH)患者至关重要。我们生成了一个特定的预后模型(里尔模型),以便尽早识别适合替代疗法的患者。320例接受皮质类固醇前瞻性治疗的AH患者被纳入开发队列,118例被纳入验证队列。测试了基线数据和第7天胆红素的变化。该模型通过逻辑回归生成。结合六个可重复变量(年龄、肾功能不全、白蛋白、凝血酶原时间、胆红素以及第7天胆红素的变化)的模型对6个月时的死亡具有高度预测性(P<0.000001)。里尔模型的受试者工作特征曲线下面积(AUROC)为0.89±0.02,高于Child-Pugh评分(0.62±0.04,P<0.00001)或Maddrey评分(0.66±0.04,P<0.00001)。在验证队列中,其AUROC为0.85±0.04,仍高于其他模型,包括MELD评分(0.72±0.05,P = 0.01)和格拉斯哥评分(0.67±0.05,P = 0.0008)。高于理想临界值0.45的患者与其他患者相比,6个月生存率显著降低:25%±3.8%对85%±2.5%,P<0.0001。该临界值能够识别约75%的观察到的死亡病例。

结论

在迄今为止最大的重度AH患者队列中,我们证明“无反应者”这一术语现在可扩展到里尔评分高于0.45的患者,这占病例的40%。根据里尔模型早期识别有高死亡风险的患者将改善重度AH患者的管理,并有助于设计未来的替代疗法研究。

相似文献

1
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.里尔模型:用于接受类固醇治疗的重症酒精性肝炎患者治疗策略的新工具。
Hepatology. 2007 Jun;45(6):1348-54. doi: 10.1002/hep.21607.
2
Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.接受类固醇治疗的重症酒精性肝炎患者的感染:治疗的早期反应是关键因素。
Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.
3
Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis.联合应用肝脏疾病评分系统的数据可更好地预测酒精性肝炎患者的预后。
Gastroenterology. 2015 Aug;149(2):398-406.e8; quiz e16-7. doi: 10.1053/j.gastro.2015.04.044. Epub 2015 Apr 29.
4
The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis.酒精摄入量的多少对患有酒精性肝炎的墨西哥患者的短期死亡率有负面影响。
Am J Gastroenterol. 2011 Aug;106(8):1472-80. doi: 10.1038/ajg.2011.141. Epub 2011 May 10.
5
Treatment of severe forms of alcoholic hepatitis: where are we going?重症酒精性肝炎的治疗:我们何去何从?
J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S60-2. doi: 10.1111/j.1440-1746.2007.05286.x.
6
Validation of prognostic scores for clinical use in patients with alcoholic hepatitis.酒精性肝炎患者临床应用预后评分的验证
Scand J Gastroenterol. 2011 Sep;46(9):1127-32. doi: 10.3109/00365521.2011.587200. Epub 2011 May 18.
7
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort.酒精性肝炎短期死亡率的九种评分模型:在经活检证实的队列中的交叉验证
Aliment Pharmacol Ther. 2014 Apr;39(7):721-32. doi: 10.1111/apt.12654.
8
The management of alcoholic hepatitis: a prospective comparison of scoring systems.酒精性肝炎的治疗:评分系统的前瞻性比较。
Aliment Pharmacol Ther. 2013 Sep;38(6):603-10. doi: 10.1111/apt.12414. Epub 2013 Jul 23.
9
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score.酒精性肝炎死亡率预测因素分析及格拉斯哥酒精性肝炎评分的推导与验证。
Gut. 2005 Aug;54(8):1174-9. doi: 10.1136/gut.2004.050781.
10
Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.粒细胞集落刺激因子对类固醇治疗部分或无反应的严重酒精性肝炎患者的疗效(GRACIAH试验):一项随机对照试验的研究方案
Trials. 2018 Dec 22;19(1):696. doi: 10.1186/s13063-018-3092-7.

引用本文的文献

1
Patient factors in responders and non-responders treated with steroids for acute alcohol-associated hepatitis.接受类固醇治疗的急性酒精性肝炎应答者和无应答者的患者因素。
World J Hepatol. 2025 Aug 27;17(8):108677. doi: 10.4254/wjh.v17.i8.108677.
2
Indian National Association for the Study of Liver (INASL) Guidance Statements for Determining Futility in Liver Transplantation.印度国家肝脏研究协会(INASL)关于判定肝移植无意义的指导声明。
J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102539. doi: 10.1016/j.jceh.2025.102539. Epub 2025 Mar 28.
3
Liver Transplantation in Alcohol-Associated Liver Disease.
酒精性肝病的肝移植
Clin Liver Dis. 2025 May;29(2):165-184. doi: 10.1016/j.cld.2024.12.001. Epub 2025 Jan 30.
4
Alcohol related hepatitis in intensive care units: clinical and biological spectrum and mortality risk factors: a multicenter retrospective study.重症监护病房中与酒精相关的肝炎:临床和生物学特征及死亡风险因素:一项多中心回顾性研究
Ann Intensive Care. 2025 Apr 15;15(1):53. doi: 10.1186/s13613-025-01450-2.
5
Predictors and prognosticators of outcomes in alcoholic hepatitis: A retrospective single center study.酒精性肝炎预后的预测因素和预后指标:一项回顾性单中心研究。
World J Hepatol. 2025 Feb 27;17(2):102152. doi: 10.4254/wjh.v17.i2.102152.
6
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol-Associated Hepatitis: A Global Cohort Study.酒精性肝炎中预测皮质类固醇反应的动态模型比较:一项全球队列研究
Aliment Pharmacol Ther. 2025 Apr;61(8):1391-1395. doi: 10.1111/apt.70024. Epub 2025 Feb 18.
7
Current and emerging therapies for alcohol-associated hepatitis.酒精性肝炎的现有及新兴疗法
Liver Res. 2023 Mar 15;7(1):35-46. doi: 10.1016/j.livres.2023.03.002. eCollection 2023 Mar.
8
Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space-time coordinates as prognostic tool and therapeutic target.酒精性肝炎三级医疗时间的前瞻性研究:时空坐标作为预后工具和治疗靶点。
Alcohol Alcohol. 2025 Jan 19;60(2). doi: 10.1093/alcalc/agae092.
9
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.利用粪便微生物群移植在严重酒精性肝炎治疗中进行以精准医学为导向的创新。
EPMA J. 2024 Oct 31;15(4):677-692. doi: 10.1007/s13167-024-00381-5. eCollection 2024 Dec.
10
Survival Benefit From Corticosteroids in Severe Alcohol-associated Hepatitis Attributed to Clinical and Treatment Differences in a Large Multicenter Cohort.大型多中心队列中临床和治疗差异导致皮质类固醇对严重酒精性肝炎具有生存获益。
Clin Transl Gastroenterol. 2025 Jan 1;16(1):e00791. doi: 10.14309/ctg.0000000000000791.